Seeking Alpha
16 Sept 2026, 07:41 UTC · 3h ago
Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Rademikibart Phase 2 Study for Acute Asthma Exacerbations Transcript
Verdict
Headline takes no side. We score CNTB +0.30 — moderately bullish.
- Expected · CNTB
+0.30moderately bullish
−1 bearish0bullish +1More positive than 60% of ticker scores this week





